4//SEC Filing
Prichard Heather Ledbetter 4
Accession 0001818382-24-000229
CIK 0001818382other
Filed
Dec 19, 7:00 PM ET
Accepted
Dec 20, 5:09 PM ET
Size
6.4 KB
Accession
0001818382-24-000229
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Prichard Heather Ledbetter
Chief Operating Officer
Transactions
- Award
Stock Options (right to buy)
2024-12-19+525→ 2,625 totalExercise: $10.28From: 2024-12-19Exp: 2030-12-14→ Common Stock (525 underlying)
Footnotes (1)
- [F1]On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vested as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application ("BLA") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021 and one-fifth of the option grant on a Form 4 filed on December 12, 2023. On December 19, 2024, Humacyte received FDA approval for its acellular tissue engineered vessel product candidate for an indication in vascular trauma. Accordingly, columns 5 and 7 of Table II report the number of securities equal to the final one-fifth of the 12/14/2020 option grant.
Documents
Issuer
Humacyte, Inc.
CIK 0001818382
Entity typeother
Related Parties
1- filerCIK 0001877712
Filing Metadata
- Form type
- 4
- Filed
- Dec 19, 7:00 PM ET
- Accepted
- Dec 20, 5:09 PM ET
- Size
- 6.4 KB